Retatrutide TRIUMPH-1 was evaluated in a new phase 3 trial involving adults with obesity without diabetes. Over 80 weeks, the study compared three retatrutide dose groups with placebo and also examined knee osteoarthritis pain and obstructive sleep apnoea in predefined subgroups. The paper is useful because it reports several outcomes in one large randomised study, while still leaving important questions for later research.
Contents
What did the retatrutide TRIUMPH-1 study test?
The trial was randomised and double-blind, meaning participants were assigned by a trial procedure and the treatment allocation was concealed during the study. A total of 2,339 adults were randomised. Participants received once-weekly subcutaneous retatrutide at 4 mg, 9 mg, or 12 mg, or placebo, for 80 weeks. The study population had obesity but did not have diabetes. These details matter because the findings apply to the population and design that the authors studied, not automatically to every group or every research setting.
What happened to body weight?
The authors reported mean body-weight changes of minus 17.6% in the 4 mg group, minus 23.7% in the 9 mg group, and minus 25.0% in the 12 mg group. The placebo group had a mean change of minus 3.9%. Compared with placebo, the differences were 19.8 percentage points for the 9 mg comparison and 21.0 percentage points for the 12 mg comparison. Both comparisons had P values below 0.001. These are trial-level averages, not a prediction for an individual, and the paper describes a research intervention rather than a laboratory reagent supplied for human use.
What did the subgroup analyses show?
Two additional outcomes were examined in predefined subgroups. The knee osteoarthritis subgroup included 574 participants, and pain was measured with the WOMAC scale, where higher scores indicate worse pain. The authors reported greater reductions in pain scores in the retatrutide groups than in the placebo group under both the hybrid-treatment and intention-to-treat analyses.
The obstructive sleep apnoea subgroup included 243 participants. The paper reported reductions in the apnoea-hypopnoea index, measured as events per hour, in the retatrutide groups compared with placebo. The authors used more than one estimand because events occurring after treatment changes or discontinuation can affect how a clinical trial is interpreted. That statistical choice should be read alongside the population, the missing-data assumptions, and the subgroup sizes.
What remains uncertain?
The abstract reports that gastrointestinal adverse events were the most common adverse events, but a short summary cannot replace the full paper or its detailed safety tables. The study was funded by Eli Lilly, and the paper identifies ClinicalTrials.gov number NCT05929066. Longer-term follow-up, comparisons across populations, and independent analyses may add context. The trial also does not establish that a research-use-only product is equivalent to the pharmaceutical product studied in the clinical trial.
For readers assessing the paper, three distinctions are especially important. First, the trial studied a clinical formulation under a controlled protocol, so its findings should not be used as a claim about unrelated research materials. Second, the body-weight endpoint and the subgroup endpoints used different analysis strategies, which means their estimates should not be compared as if they were the same measurement. Third, a statistically significant difference describes the observed comparison in this trial. It does not settle questions about mechanism, durability, external validity, or how findings may differ in another population.
Related on Peptra Labs
For background, see the retatrutide research guide and the retatrutide catalogue page. The receptor comparison guide provides wider context for how these compounds are discussed in research. These pages are reference material and do not change the clinical evidence reported in the paper.
References
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026. PubMed.
- TRIUMPH-1, ClinicalTrials.gov identifier NCT05929066. ClinicalTrials.gov.
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
